Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Metcalfe

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
The New Zealand Medical Journal|February 25, 2016
Fast, fair climate action crucial for health and equityScott Metcalfe
Lancet (London, England)|February 28, 2003
Old letters, new rulesScott Metcalfe
The New Zealand Medical Journal|August 7, 2012
PHARMAC's updated guidelines for cost-utility analyses, with new QALYs per $1M metricRachel Grocott, Scott Metcalfe
The New Zealand Medical Journal|July 27, 2007
PHARMAC's updated guidelines for cost-effectiveness analyses, with new discount rateRachel Grocott, Scott Metcalfe
The New Zealand Medical Journal|November 16, 2005
PHARMAC's response on gemcitabine and transparencySteffan Crausaz, Scott Metcalfe
International Journal of Environmental Research and Public Health|July 10, 2010
Comments on "Simoens, S. Health economic assessment: a methodological primer. Int. J. Environ. Res. Public Health 2009, 6, 2950-2966"-New Zealand in fact has no cost-effectiveness thresholdScott Metcalfe, Rachel Grocott
The New Zealand Medical Journal|November 16, 2005
PHARMAC responds on long-acting inhalers for COPDScott Metcalfe, Sean Dougherty
The New Zealand Medical Journal|October 15, 2005
Going against the flow: the impact of PHARMAC not funding COX-2 inhibitors for chronic arthritisRachel Grocott, Scott Metcalfe
The Journal of Allergy and Clinical Immunology|March 10, 2004
Seretide meta-analysis missed important features and overstates any advantages over concurrent LABA/ICS devicesScott Metcalfe, Peter Moodie
The New Zealand Medical Journal|February 8, 2006
More on PHARMAC and tobacco control in New ZealandScott Metcalfe, Peter Moodie
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
The New Zealand Medical Journal|February 25, 2016
Fast, fair climate action crucial for health and equityScott Metcalfe
Lancet (London, England)|February 28, 2003
Old letters, new rulesScott Metcalfe
The New Zealand Medical Journal|August 7, 2012
PHARMAC's updated guidelines for cost-utility analyses, with new QALYs per $1M metricRachel Grocott, Scott Metcalfe
The New Zealand Medical Journal|July 27, 2007
PHARMAC's updated guidelines for cost-effectiveness analyses, with new discount rateRachel Grocott, Scott Metcalfe
The New Zealand Medical Journal|November 16, 2005
PHARMAC's response on gemcitabine and transparencySteffan Crausaz, Scott Metcalfe
International Journal of Environmental Research and Public Health|July 10, 2010
Comments on "Simoens, S. Health economic assessment: a methodological primer. Int. J. Environ. Res. Public Health 2009, 6, 2950-2966"-New Zealand in fact has no cost-effectiveness thresholdScott Metcalfe, Rachel Grocott
The New Zealand Medical Journal|November 16, 2005
PHARMAC responds on long-acting inhalers for COPDScott Metcalfe, Sean Dougherty
The New Zealand Medical Journal|October 15, 2005
Going against the flow: the impact of PHARMAC not funding COX-2 inhibitors for chronic arthritisRachel Grocott, Scott Metcalfe
The Journal of Allergy and Clinical Immunology|March 10, 2004
Seretide meta-analysis missed important features and overstates any advantages over concurrent LABA/ICS devicesScott Metcalfe, Peter Moodie
The New Zealand Medical Journal|February 8, 2006
More on PHARMAC and tobacco control in New ZealandScott Metcalfe, Peter Moodie
Pageof 7